Determining the Clinical Characteristics, Treatment Strategies, and Prognostic Factors for Mycoplasma pneumoniae Encephalitis in Children: A Multicenter Study in China
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Most of the knowledge of Mycoplasma pneumonia (M. pneumoniae) encephalitis (MPE) in children is based on case reports or small case series. This study aimed to describe the clinical features and prognostic factors of MPE, and the efficacy of azithromycin with or without immunomodulatory therapy. Methods The medical data of 87 patients with MPE from 3 medical centers in southwestern China over a 7-year period were reviewed. Results MPE was found in children of all ages except for neonates. The most common neurological manifestations included consciousness disturbance (90%) and headache (87.4%), the most common extraneurological manifestations included fever (96.5%) and respiratory system involvement (94.3%); multisystem involvement (98.2%) and elevated C-reactive protein (CRP) (90.8%) were also prominent. M. pneumoniae was detected in cerebrospinal fluid (CSF) less often than in blood and respiratory tract secretions. Azithromycin with intravenous immunoglobulin or/and corticosteroid treatment can shorten the hospitalization duration and the clinical improvement process. Most patients (82.8%) received a favorable prognosis; serum lactate dehydrogenase (LDH) and CSF protein levels were higher in the poor-outcome group than in the good-outcome group (p<0.05). Neurological sequelae are likely to continue when the onset of this condition occurs during teenage years. Conclusions MPE generally presented with nonspecific clinical manifestations. In children with acute encephalitis accompanied by multi-system involvement and prominently elevated CRP, M. pneumoniae should be considered as a possible pathogen. Immunomodulating therapies should be recommended regardless of the duration of the prodromal period. High CSF protein level, blood LDH elevation, and higher age may be associated with an unfavorable outcome.
Abstract
Background and Purpose Most of the knowledge of Mycoplasma pneumonia (M. pneumoniae) encephalitis (MPE) in children is based on case reports or small case series. This study aimed to describe the clinical features and prognostic factors of MPE, and the efficacy of azithromycin with or without immunomodulatory therapy. Methods The medical data of 87 patients with MPE from 3 medical centers in southwestern China over a 7-year period were reviewed. Results MPE was found in children of all ages except for neonates. The most common neurological manifestations included consciousness disturbance (90%) and headache (87.4%), the most common extraneurological manifestations included fever (96.5%) and respiratory system involvement (94.3%); multisystem involvement (98.2%) and elevated C-reactive protein (CRP) (90.8%) were also prominent. M. pneumoniae was detected in cerebrospinal fluid (CSF) less often than in blood and respiratory tract secretions. Azithromycin with intravenous immunoglobulin or/and corticosteroid treatment can shorten the hospitalization duration and the clinical improvement process. Most patients (82.8%) received a favorable prognosis; serum lactate dehydrogenase (LDH) and CSF protein levels were higher in the poor-outcome group than in the good-outcome group (p<0.05). Neurological sequelae are likely to continue when the onset of this condition occurs during teenage years. Conclusions MPE generally presented with nonspecific clinical manifestations. In children with acute encephalitis accompanied by multi-system involvement and prominently elevated CRP, M. pneumoniae should be considered as a possible pathogen. Immunomodulating therapies should be recommended regardless of the duration of the prodromal period. High CSF protein level, blood LDH elevation, and higher age may be associated with an unfavorable outcome.
참고문헌 (35)
- Bitnun A, "Mycoplasma pneumoniae ecephalitis", Semin Pediatr Infect Dis, 14, pp.96~107 (2003)
- Tsiodras S, "Central nervous system manifestations of Mycoplasma pneumoniae infections", J Infect, 51, pp.343~354 (2005)
- Yiş U, "Mycoplasma pneumoniae : nervous system complications in childhood and review of the literature", Eur J Pediatr, 167, pp.973~978 (2008)
- Yimenicioğlu S, "Mycoplasma pneumoniae infection with neurologic complications", Iran J Pediatr, 24, pp.647~651 (2014)
- Bitnun A, "Acute childhood encephalitis and Mycoplasma pneumoniae", Clin Infect Dis, 32, pp.1674~1684 (2001)
- Kammer J, "Neurological manifestations of Mycoplasma pneumoniae infection in hospitalized children and their long-term follow-up", Neuropediatrics, 47, pp.308~317 (2016)
- Narita M, "Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis", Front Microbiol, 7, pp.2~ (2016)
- D’Alonzo R, "Pathogenesis and treatment of neurologic diseases associated with Mycoplasma pneumoniae infection", Front Microbiol, 9, pp.2751~ (2018)
- Daba M, "Intravenous immunoglobulin as a therapeutic option for Mycoplasma pneumoniae encephalitis", J Child Neurol, 34, pp.687~691 (2019)
- Chambert-Loir C, "Immediate relief of Mycoplasma pneumoniae encephalitis symptoms after intravenous immunoglobulin", Pediatr Neurol, 41, pp.375~377 (2009)
- Daxboeck F, "Mycoplasma pneumoniae central nervous system infections", Curr Opin Neurol, 19, pp.374~378 (2006)
- Daxboeck F, "Diagnosis, treatment, and prognosis of Mycoplasma pneumoniae childhood encephalitis : systematic review of 58 cases", J Child Neurol, 19, pp.865~871 (2004)
- Takanashi J, "Differences in the time course of splenial and white matter lesions in clinically mild encephalitis", encephalopathy with a reversible splenial lesion(MERS), 2010, pp.292, 24~27
- Sun D, "Clinico-radiological characteristics of children with mild encephalitis", encephalopathy with a reversible splenial lesion, 2015, pp.33, 929~932
- Atkinson TP, "Mycoplasma pneumoniae infections in childhood", Pediatr Infect Dis J, 33, pp.92~94 (2014)
- Meyer Sauteur PM, "Mycoplasma pneumoniae-associated encephalitis in childhood--nervous system disorder during or after a respiratory tract infection", Klin Padiatr, 223, pp.209~213 (2011)
- Ismail FY, "Cerebral plasticity : windows of opportunity in the developing brain", Eur J Paediatr Neurol, 21, pp.23~48 (2017)
- Chen KM, "Clinical manifestations of Japanese encephalitis in southern Taiwan", J Microbiol Immunol Infect, 42, pp.296~302 (2009)
- Xie Y, "A population-based acute meningitis and encephalitis syndromes surveillance in Guangxi, China, May 2007-June 2012", PLoS One, 10, pp.e0144366~ (2015)
- Asgari M, "Barrier dysfunction or drainage reduction : differentiating causes of CSF protein increase", Fluids Barriers CNS, 14, pp.14~ (2017)
- Lo SH, "Determining the clinical characteristics and prognostic factors for the outcomes of Japanese encephalitis in adults : a multicenter study from southern Taiwan", J Microbiol Immunol Infect, 52, pp.893~901 (2019)
- Klein R, "Clinical and diagnostic significance of lactate dehydrogenase and its isoenzymes in animals", Vet Med Int, 2020, pp.5346483~ (2020)
- Wu Y, "Serum lactate dehydrogenase activities as systems biomarkers for 48 types of human diseases", Sci Rep, 11, pp.12997~ (2021)
- Kumar P, "Analysis of cell viability by the lactate dehydrogenase assay", Cold Spring Harb Protoc, 2018, pp.95497~ (2018)
- Huang L, "Independent predictors for longer radiographic resolution in patients with refractory Mycoplasma pneumoniae pneumonia : a prospective cohort study", BMJ Open, 8, pp.e023719~ (2018)
- Lu A, "Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae pneumonia in children", Respir Care, 60, pp.1469~1475 (2015)
- Anan M, "Lactate and lactate dehydrogenase in cistern as biomarkers of early brain injury and delayed cerebral ischemia of subarachnoid hemorrhage", J Stroke Cerebrovasc Dis, 29, pp.104765~ (2020)
- Liu Y, "The significance of the detection of serum lactate dehydrogenase, hypersensitive C-reactive protein, and N-terminal pro-brain natriuretic peptide for the evaluation of the severity and progression of pediatric patients with traumatic brain injury", Curr Neurovasc Res, 19, pp.219~224 (2022)
- Rhodes RH, "Mycoplasmal cerebral vasculopathy in a lymphoma patient : presumptive evidence of Mycoplasma pneumoniae microvascular endothelial cell invasion in a brain biopsy", J Neurol Sci, 309, pp.18~25 (2011)
- Riedel K, "Acute disseminated encephalomyelitis(ADEM)due to Mycoplasma pneumoniae infection in an adolescent", Infection, 29, pp.240~242 (2001)
- Pereyre S, "Mycoplasma pneumoniae : current knowledge on macrolide resistance and treatment", Front Microbiol, 7, pp.974~ (2016)
- Sandman Z, "Azithromycin" (2022), StatPearls Publishing
- Liu H, "A systematic review of the therapy for Mycoplasma pneumoniae infections in children", Zhonghua Er Ke Za Zhi, 54, pp.111~118 (2016)
- Bajantri B, "Mycoplasma pneumoniae : a potentially severe infection", J Clin Med Res, 10, pp.535~544 (2018)
- Parrott GL, "A compendium for Mycoplasma pneumoniae", Front Microbiol, 7, pp.513~ (2016)